NPC: EBV DNA load predicts ICT outcomes in Chinese study

  • Huang CL & al.
  • Int J Radiat Oncol Biol Phys
  • 22 Jan 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A retrospective study suggests that detectable levels of Epstein-Barr virus (EBV) DNA after induction chemotherapy (ICT) are associated with poor survival outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (NPC).

Why this matters

  • Predicting patient prognosis can assist risk stratification and treatment planning.

Key results

  • Presence of post-ICT EBV DNA was associated with reduced 3-year OS (86.4% vs 93.4%; HR, 2.567; P=.029), distant metastasis-free survival (69.2% vs 93.9%; HR, 5.618; P<.001 and dfs vs hr compared with absence of post-ict ebv dna in multivariate analysis.>
  • Post-ICT EBV DNA had areas under the curve of 0.584, 0.717, and 0.659 for predicting 3-year death, metastasis, and disease failure, respectively (P<.001 for all>

Study design

  • 278 patients with stage III-IV NPC treated with ICT followed by concurrent chemoradiotherapy were analyzed for associations between EBV DNA and survival outcomes.
  • Funding: Natural Science Foundation of Guangdong Province; Natural Science Foundation of China; Health & Medical Collaborative Innovation Project of Guangzhou City; Innovation Team Development Plan of the Ministry of Education; Overseas Expertise Introduction Project for Discipline Innovation.

Limitations

  • Retrospective study.